Network origin in Benoit de Chassey first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.
15
| Holding Company | Biotechnology | 15 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Benoit de Chassey via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Circassia Ltd.
 Circassia Ltd. Pharmaceuticals: OtherHealth Technology Circassia Ltd. develops medicines for allergic and auto-immune diseases. The company was founded by Anthony Barrington Kay and Mark Larché on December 29, 1998 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member | |
| POXEL | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Chief Tech/Sci/R&D Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Bath | College/University | Undergraduate Degree Undergraduate Degree | |
| CHUGAI PHARMACEUTICAL CO., LTD | Pharmaceuticals: Major | Corporate Officer/Principal | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Director/Board Member | |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Investment Committee Member Private Equity Investor | |
| SCYNEXIS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Chemicals: Specialty | Corporate Officer/Principal | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| WEIFA ASA | Pharmaceuticals: Major | Director/Board Member | |
| Université de Bordeaux | College/University | Doctorate Degree | |
| SPEXIS AG | Pharmaceuticals: Major | Director/Board Member | |
| University of Paris Jussieu | College/University | Doctorate Degree | |
| EM Lyon Business School | College/University | Undergraduate Degree | |
| École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin | |
| Institut National des Sciences Appliquées de Toulouse | College/University | Undergraduate Degree | |
| SARTORIUS STEDIM BIOTECH | Medical Specialties | Director/Board Member | |
BPIFrance Investissement SAS
 BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Investment Managers | Private Equity Investor Private Equity Investor | |
| TXCELL | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| QIAGEN MARSEILLE | Miscellaneous Commercial Services | Director of Finance/CFO | |
| VOLUNTIS S.A. | Packaged Software | Director/Board Member | |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Spark Therapeutics Ireland Ltd.
 Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Chairman | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman | |
| BIOM'UP | Medical Specialties | Director/Board Member | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Chairman | |
BioAster
 BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | Miscellaneous Commercial Services | Director of Finance/CFO | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| Inatherys SAS | Director/Board Member | ||
| NIOX GROUP PLC | Medical/Nursing Services | Director/Board Member | |
Inotrem SA
 Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Founder Director/Board Member | |
| LYSOGENE | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Mironid Ltd.
 Mironid Ltd. Pharmaceuticals: MajorHealth Technology Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member | |
| Abcd Ltd. | Director/Board Member | ||
Apic Bio, Inc.
 Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | Packaged Software | Director/Board Member | |
Mediar Therapeutics, Inc.
 Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Citryll BV
 Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Novadiscovery SAS
 Novadiscovery SAS Information Technology ServicesTechnology Services Novadiscovery SAS develops mathematical model and artificial intelligence solutions for the healthcare sector. It offers risk management analytic tools for medical research programs and clinical trials. The company was founded by Fr?d?ric Cogny, Jean-Pierre Boissel, and Fran?ois-Henri Boissel in 2010 and is headquartered in Lyon, France. | Information Technology Services | Director of Finance/CFO |
Statistics
International
| France | 25 |
| United States | 8 |
| United Kingdom | 8 |
| Switzerland | 7 |
| Japan | 2 |
Sectoral
| Health Technology | 27 |
| Consumer Services | 7 |
| Commercial Services | 7 |
| Finance | 4 |
| Technology Services | 4 |
Operational
| Director/Board Member | 115 |
| Corporate Officer/Principal | 38 |
| Independent Dir/Board Member | 23 |
| Chairman | 20 |
| Founder | 13 |
Most connected contacts
| Insiders | |
|---|---|
| Iain Dukes | 30 |
| Maina Bhaman | 26 |
| Rafaèle Elisabeth Tordjman | 23 |
| Jason Robert Dinges | 22 |
| Laurent Arthaud | 21 |
| Jean-Jacques Garaud | 17 |
| Laurent Higueret | 14 |
| Timothy M. Wright | 13 |
| Annette Clancy | 10 |
| Jacky Vonderscher | 9 |
| Pascale Boissel | 8 |
| Eric Meldrum | 3 |
| Vincent Lotteau | 1 |
| Patrice André | 1 |
| Laurène Meyniel-Schickl | 1 |
- Stock Market
- Insiders
- Benoit de Chassey
- Company connections